Last month, a phase 3 trial called CASPIAN met its primary endpoint with Imfinzi by delivering a statistically-significant and clinically-meaningful improvement in overall survival for patients suffering from
The post AstraZeneca’s Imfinzi gets FDA orphan drug status for small cell lung cancer appeared first on Pharmaceutical Business review.